S

Sanofi

Global pharma company; vaccines and R&D

Treasury Analyst German Speaker

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
€70.4k - €93.9k
Junior
Bachelor's
Brussels, Belgium
HybridHybrid: 3 days on site and 2 days home office; few travels expected.
Finance & BankingTreasury

About the job

Requirements
  • A Bachelor's degree in Finance, Economics, Business Administration, or a related field is required.
  • A minimum of 2 years of treasury experience in a corporate environment is required.
  • Proficiency in S4/SAP, FxNet for hedging, TREMA for cash flow reporting, and Microsoft Office Suite, including Excel and PowerPoint, is required.
  • Strong analytical and financial acumen and exceptional attention to detail are required.
  • Advanced knowledge of treasury operations, cash management, and foreign exchange risk management is required.
  • Understanding of banking products, payment systems, and regulatory requirements is required.
  • Proficiency in financial modeling and reporting tools is required.
  • Ability to establish and maintain working relationships with internal stakeholders and external banking partners is required.
  • Excellent verbal and written communication skills, including the ability to present complex information clearly, are required.
  • A proactive, solution-oriented approach and ability to work collaboratively are required.
  • Ability to work in a fast-paced international environment with changing priorities is required.
  • High ethical standards and commitment to compliance are required.
  • Fluent written and spoken English and German are required.
Responsibilities
  • Execute daily operational treasury management activities across the assigned geographical region.
  • Reconcile bank flows with forecasts and maintain optimal bank account balancing.
  • Prepare daily cash positions and rolling liquidity forecasts for centralized countries to ensure adequate financing of shortages and optimal placement of surpluses.
  • Execute treasury-related payment activities, including wire transfers, electronic funds transfers, intercompany loan and deposit settlements, and other treasury transactions.
  • Deliver actual and forecast cash flow reporting and analysis for internal and external stakeholders.
  • Conduct working capital analysis, including Cash Conversion Cycle KPIs with focus on DSO (Budget, Actuals, Forecast), DPO, DIO, and customer overdue management.
  • Identify opportunities for cash flow optimization and working capital efficiency improvements.
  • Report FX exposures accurately and promptly and manage subsequent settlements for centralized countries.
  • Monitor and report FX gains and losses and ensure compliance with hedging policies.
  • Support implementation of FX risk mitigation strategies.
  • Manage bank account operations, including opening and closing accounts and overdrafts, and maintain banking authorization matrices.
  • Serve as the primary contact for local banks on treasury operational matters and ensure high-quality service delivery.
  • Maintain local banking and payment systems in accordance with Group policies.
  • Monitor and control bank fees to optimize costs.
  • Maintain comprehensive documentation for treasury business processes.
  • Review and update procedures to ensure compliance with internal control requirements and regulatory standards.
  • Support audit activities and implement control improvements as needed.
  • Provide operational support to Global Treasury Operations for M&A, business development, and divestment activities.
  • Participate in process improvement initiatives and technology implementations to enhance operational efficiency.
  • Collaborate with the IT function on system enhancements and process optimization projects.
  • Manage annual insurance renewal processes with local brokers, including data consolidation and analysis, where applicable.
  • Support Global Treasury Operations on legal and tax activities, including dividend payments, legal restructurings, and intercompany loan management.
  • Maintain accurate local intercompany loan schedules and documentation.
Desired Qualifications
  • Previous finance experience in an international, multi-country environment is preferred.
  • Knowledge of cash management and treasury systems is preferred.
  • Experience with accounting and/or financial analysis is preferred.
  • Familiarity with Treasury Management Systems, particularly the S/4HANA Treasury System, is preferred.
  • A professional treasury certification such as CTP, ACT, or equivalent is advantageous.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...